ValuEngine lowered shares of TERUMO CORP/ADR (OTCMKTS:TRUMY) from a buy rating to a hold rating in a report issued on Tuesday, ValuEngine reports.

Separately, Zacks Investment Research upgraded shares of TERUMO CORP/ADR from a sell rating to a hold rating in a report on Thursday, March 14th.

TRUMY opened at $53.02 on Tuesday. The firm has a market capitalization of $22.03 billion, a price-to-earnings ratio of 24.21, a PEG ratio of 3.72 and a beta of 0.38. TERUMO CORP/ADR has a 12-month low of $51.19 and a 12-month high of $63.83.


Terumo Corporation develops, manufactures, and distributes medical devices and services worldwide. It provides products for use in cardiothoracic surgery, interventional procedure, and medicine transfusion. The company offers vascular intervention devices, such as introducer sheathes, guide wires, angiographic catheters, and radial artery compression devices; therapeutic devices; and intravascular imaging systems, including optical frequency domain imaging and intravascular ultrasound systems.

Read More: What is the QQQ ETF?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for TERUMO CORP/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TERUMO CORP/ADR and related companies with's FREE daily email newsletter.